Generics - Mylan Laboratories, Diabetes

Filter

Popular Filters

Mylan extends deal with Biocon to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBioconBiotechnologyDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Watson gets FDA final approval for generic Actos; negative news on Prochieve appeal

29-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) said on Friday that it has launched a generic…

ActosDiabetesGenericsLegalMylan LaboratoriesNorth AmericaProchieveRegulationReproductiveTakeda PharmaceuticalsWatson Pharmaceuticals

Mylan confirms Actoplus patent challenge

09-01-2012

US generic drugmaker Mylan (Nasdaq: MYL) has confirmed that it has been sued by Takeda Pharmaceutical…

AndrxDiabetesGenericsLegalMylan LaboratoriesNorth AmericaPatentsTakeda PharmaceuticalsWatson Pharmaceuticals

Back to top